Prior authorizations for dermatologic medications: An American Academy of Dermatology survey of US dermatology providers and staff - 14/09/17
Doi : 10.1016/j.jaad.2017.05.008
Aaron M. Secrest, MD, PhD a, ⁎ 
, Maryam M. Asgari, MD, MPH b, Arianne S. Kourosh, MD, MPH b, John S. Barbieri, MD, MBA c, Joerg Albrecht, MD d
for the
, Maryam M. Asgari, MD, MPH b, Arianne S. Kourosh, MD, MPH b, John S. Barbieri, MD, MBA c, Joerg Albrecht, MD dfor the
American Academy of Dermatology Drug Pricing and Transparency Task Force
a Departments of Dermatology and Population Health Sciences, University of Utah, Salt Lake City, Utah
b Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
c Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
d Division of Dermatology, Department of Medicine, J.H. Stroger Hospital of Cook County, Chicago, Illinois
∗Correspondence to: Aaron M. Secrest, MD, PhD, Department of Dermatology, University of Utah, 30 N 1900 E, 4A330, Salt Lake City, UT 84132Department of DermatologyUniversity of Utah30 N 1900 E, 4A330Salt Lake CityUT84132
| Funding sources: None. |
|
| Dr Asgari is a principal investigator on research grants for Valeant Pharmaceuticals and Pfizer. Dr Albrecht is a clinical investigator for studies sponsored by Abbvie. Drs Secrest, Kourosh, and Barbieri have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 77 - N° 4
P. 784-786 - octobre 2017 Retour au numéro
Article précédent
- Sex and leadership in academic dermatology: A nationwide survey
- Connie R. Shi, Suzanne Olbricht, Ruth Ann Vleugels, Vinod E. Nambudiri
- Medication nonadherence in dermatology: Divergent ethical implications for patient care
- Grant R. Plost, Benjamin K. Stoff
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?